Innovative approaches in detecting cancer: living biocomputers

Marta R. Casanova

Universidade do Minho, Braga, Portugal

Colorectal cancer is one of the deadliest forms of cancer, causing nearly one million deaths every year. Early detection can dramatically improve survival rates, as discovering cancer in its early stages often allows for more effective treatment. However, current methods for detecting colorectal cancer are far from ideal. Colonoscopies and stool tests are invasive, uncomfortable, and time-consuming, which discourages many people from undergoing regular screenings. Blood-based tests can detect cancer signals, but they are expensive and only offer a brief snapshot of tumour activity at the time of testing. This limits their effectiveness, especially for monitoring cancer recurrence or progression. In fact, many colorectal cancer deaths occur due to recurrent disease, often emerging after initial treatment. These recurrences are frequently diagnosed at an advanced stage, in part because current monitoring tools are inadequate for regular, long-term follow-up of patients.

To tackle this challenge, the team is developing a groundbreaking new approach: a living biosensor. This biosensor is created using specially engineered bacteria, which act as tiny sentinels capable of detecting cancer signals in liquid samples — with the potential to operate inside the body in future versions. When exposed to specific biomarkers, the bacteria emit a fluorescent signal that can be observed in real time. This innovative system works continuously, offering a non-invasive, low-cost, and easy-to-use method for monitoring cancer over time. Unlike traditional methods, it does not rely on periodic invasive testing, making it a more accessible and scalable tool for early detection and follow-up.

The first phase of this research focuses on validating the biosensor in synthetic fluids to ensure it can reliably detect specific cancer markers associated with colorectal cancer. If successful, this technology could be expanded to detect a broader range of cancer signals and be adapted for use in other cancer types. This could revolutionize cancer diagnostics, shifting the focus from late-stage detection to early, proactive intervention.

If proven effective, this living biosensor could transform how we detect and manage cancer, enabling earlier treatment and significantly improving survival rates. Beyond making diagnosis less invasive and more affordable, it would empower patients and clinicians with a reliable, continuous way to monitor health, ultimately enhancing quality of life.

Engineered Biocomputers for Real-Time Tumor Monitoring

Stage 1